Regulatory Story
Go to market news section View chart   Print
Allergy Therapeutics PLC  -  AGY   

Exercise of Options

Released 10:41 22-Jan-2013

RNS Number : 0842W
Allergy Therapeutics PLC
22 January 2013

22 January 2013


Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")


Exercise of Options



Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces it has made an application to the London Stock Exchange for 23,850 ordinary shares of 0.1p each to be admitted to trading on AIM. Dealing is expected to commence in these shares on 25 January 2013. The ordinary shares have been allotted pursuant to the exercise of options and will rank pari passu in all respects with the existing ordinary share capital of the Company.


The total number of shares in issue (inclusive of the above issue) is 409,866,831 Ordinary shares of 0.1p each.



For further information

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson / Clare Terlouw

FTI Consulting

+44 (0) 207 831 3113

Simon Conway / Susan Stuart / Victoria Foster Mitchell



This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Exercise of Options - RNS